@article{d52147cdda1944a983f8ac5484ca1e54,
title = "The C1q binding test for soluble immune complexes: Clinical correlations obtained in patients with cancer",
abstract = "Sera from 134 selected patients with various types of cancer were tested for soluble antigen-antibody complexes by the C1q binding method. Sera from 85 healthy blood bank donors served as normal controls. C1q binding activity (C1q BA) values above the 95th percentile for healthy subjects were found in 83% of sera from patients with neoplastic diseases. The incidence of abnormal C1q BA values among patients with malignant melanoma was 83%, with breast cancer 74%, with colon cancer 75%, with lung cancer 88%, with leukemia and lymphoma 85%, and with miscellaneous tumors 94%. High C1q BA values were found most frequently in sera of patients who had been diagnosed relatively recently (within 5 mo) and who had evident residual disease after surgical treatment. Recurrence or progression of tumor growth occurred significantly more frequently in lung cancer patients with high C1q BA. DNA was not detected in cancer patients{\textquoteright} sera and treatment with DNase did not decrease in C1q BA. C1q BA in sera could not be explained by the presence of antiglobulin antibodies. Sucrose density gradient ultracentrifugation studies of the serum C1q BA in 4 cancer patients showed that the major binding activity was found between 19S and 7S.",
author = "Rossen, {R. D.} and Reisberg, {M. A.} and Hersh, {E. M.} and Gutterman, {J. U.}",
note = "Funding Information: 1 Received July 12,1976; accepted November I, 1976. 2 Supported by The Veterans Administration Hospital, Houston, Tex.; and Public Health Service grants CA14984, CA05831, CA15333-03, and NOI CB33888 from the National Cancer Institute; HLl7269 from the National Heart, Lung, and Blood Institute; AMI7555 from the National Institute of Arthritis, Metabolism, and Digestive Diseases; and RR00350 from the Division of Research Resources, National Institutes of Health (NIH). 3 Departments of Microbiology and Immunology, and Medicine, Baylor College of Medicine, Texas Medical Center, Houston, Tex. 77030, and Laboratory for Immunology Research, The Veterans Administration Hospital, Houston, Tex. 77211. 4 Address reprint requests to Dr. Rossen at The Veterans Administration Hospital. , Department of Developmental Therapeutics, The University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, Tex. 77030. 6 Recipient of NIH Career Development Award CA71007-02. 7 We gratefully acknowledge the kindness of Dr. Peter Miescher in allowing R. D. Rossen to visit his laboratory to learn the Clq binding technique, and of Dr. Martin Lidsky for donations of sera from patients with active rheumatoid arthritis. We are also grateful to Dr. H. K. Thompson for helpful discussions concerning data analysis; to Caryl Reese, Connie Schimbor, and Abe Solomon for excellent technical assistance, and to Elaine Bowers for her excellent secretarial work. Computational assistance was provided by the Clinfo project, funded by Division of Research Resources, NIH contract NOI RR52118.",
year = "1977",
month = may,
doi = "10.1093/jnci/58.5.1205",
language = "English (US)",
volume = "58",
pages = "1205--1215",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "5",
}